Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Executive Summary

Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.

Advertisement

Related Content

New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value
PCSK9 Pick-Me-Up: New Cholesterol Guidelines May Mean Lower LDL Targets
Ex-US FDA Director John Jenkins Sketches Regulatory Path For Esperion's Bempedoic Acid
PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent
The Year's Clinical Trials In Review: Big Hits In 2017
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
What To Look Out For At ACC
Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098413

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel